METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE
APHP240920
Phase 3 small_molecule active
Quick answer
METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE for Cutaneous lupus erythematosus is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Cutaneous lupus erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active